Navigation Links
XLHealth Corporation Announces Executive Changes
Date:1/28/2008

- Company Elects New Board Members, Appoints New CEO -

BALTIMORE, Jan. 28 /PRNewswire/ -- XLHealth, a Baltimore-based company focused on improving the healthcare of chronically ill seniors, today announced that its largest investor, MatlinPatterson, has nominated five new directors to the company's nine-person board. The modified board has appointed Frederick C. Dunlap as the company's chief executive officer and chairman of the board.

Patrick Hervy, who will remain on XLHealth's board of directors, has stepped down as board chairman and CEO. Current board members Dr. Jeffrey Tredwell, John Woloszyn, and Robert Reffkin will also remain. XLHealth's senior management team will continue to serve in their current positions.

"Fred Dunlap is a strong leader in the healthcare industry, having held executive-level positions at some of the nation's top health plans," said XLHealth executive vice president, Paul Serini. "With Fred at the helm of XLHealth, we are confident that the company will continue to grow in what is becoming an increasingly significant arena."

Prior to joining XLHealth, Dunlap served as owner and president of BWM Ventures, Inc., a management consulting firm concentrated on the healthcare services industry. In this position, Dunlap worked with private equity investors of several portfolio companies, serving in senior leadership capacities including roles as CEO, COO, and President. In addition, Dunlap previously served as COO of AMERIGROUP, a managed healthcare organization focused on the needs of low-income Americans. Dunlap has also served in executive level positions at UnitedHealth Group, as its CEO of Florida/Puerto Rico and previously as vice president of Specialty Companies.

"I am eager to join XLHealth at such an exciting time for chronic condition Special Needs Plans," said Fred Dunlap. "I look forward to the coming year as one where, as an organization, we are focused on delivering on the promise of improving care for the nation's growing chronically ill senior population."

About XLHealth Corporation

XLHealth (http://www.xlhealth.com), which is focused on improving the healthcare of chronically ill seniors, was founded in 1997 as Diabetex by a group of business executives and physicians. XLHealth is currently the owner and operator of Care Improvement Plus, the nation's largest chronic condition Special Needs Plan (C-SNP). Headquartered in Baltimore, Md., XLHealth recently announced its acquisition of Leprechaun, LLC, a provider of technology and consulting services designed to improve efficiencies in Medicare Advantage plan member assessment, diagnosis, data management and claims. XLHealth has earned Full Accreditation from the National Committee for Quality Assurance (NCQA) under its standards for patient and practitioner-oriented accreditation of disease management programs.


'/>"/>
SOURCE XLHealth Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... TX (PRWEB) , ... September 20, 2017 , ... ... date of the much-anticipated fall event , Look Awesome This Autumn with ... personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique is ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that Clear Global ... support services market) has entered into an agreement on September 1, 2017 with ... PGSD is the first private Dental School to launch an online, accredited Post ...
(Date:9/20/2017)... ... , ... Compliancy Group is proud to announce that its ... another long-time client pass their Department of Health and Human Services (HHS) Office ... to the help of the Compliancy Group's Audit Response Program™, not a single ...
(Date:9/20/2017)... ... September 20, 2017 , ... In just a short ... has already been receiving positive feedback from customers trying the product for the first ... Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from athletes ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods ... market impact in 27 different categories. Nopavera Plus was named to the ... be announced at SupplySide West 2017 during presentations at SupplySide Central on Sept. 27 ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017  For nearly two decades, New Life Agency has been committed ... industry. Today, New Life Agency announces a powerful three-way partnership designed to ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: